Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment: Longitudinal Results From the Registry of Hypogonadism in Men (RHYME)
Autor: | Rosen, Raymond C, Wu, Frederick, Behre, Hermann M, Porst, Hartmut, Meuleman, Eric J H, Maggi, Mario, Romero-Otero, Javier, Martinez-Salamanca, Juan I, Jones, Thomas Hugh, Debruyne, Frans M J, Kurth, Karl-Heinz, Hackett, Geoff I, Quinton, Richard, Stroberg, Peter, Reisman, Yacov, Pescatori, Edoardo S, Morales, Antonio, Bassas, Lluis, Cruz, Natalio, Cunningham, Glenn R, Wheaton, Olivia A, RHYME Investigators |
---|---|
Přispěvatelé: | Urology |
Jazyk: | angličtina |
Rok vydání: | 2017 |
Předmět: |
Gerontology
Adult Male medicine.medical_specialty Hormone Replacement Therapy Urology Endocrinology Diabetes and Metabolism media_common.quotation_subject Sexual Behavior 030232 urology & nephrology Testosterone Replacement Therapy Cohort Studies 03 medical and health sciences Young Adult 0302 clinical medicine Endocrinology Quality of life (healthcare) Hormone replacement therapy (female-to-male) Phosphodiesterase Type 5 Inhibitors Medicine Humans Testosterone Longitudinal Studies Prospective Studies Registries Young adult Prospective cohort study media_common Sexual Function Aged 030219 obstetrics & reproductive medicine business.industry Rhyme Hypogonadism Penile Erection Testosterone (patch) Middle Aged Europe Psychiatry and Mental health Reproductive Medicine Physical therapy Quality of Life business Sexual function Cohort study |
Zdroj: | Journal of Sexual Medicine, 14(9), 1104-1115. Wiley-Blackwell Rosen, R C, Wu, F, Behre, H M, Porst, H, Meuleman, E, Maggi, M, Romero-Otero, J, Martinez-Salamanca, J I, Jones, T H, Debruyne, F, Kurth, K H, Hackett, G I, Quinton, R, Stroberg, P, Reisman, Y, Pescatori, E S, Morales, A, Bassas, L, Cruz, N, Cunningham, G R, Wheaton, O A & RHYME Investigators 2017, ' Quality of Life and Sexual Function Benefits of Long-Term Testosterone Treatment : Longitudinal Results From the Registry of Hypogonadism in Men (RHYME) ', Journal of Sexual Medicine, vol. 14, no. 9, pp. 1104-1115 . https://doi.org/10.1016/j.jsxm.2017.07.004 |
ISSN: | 1743-6095 |
Popis: | Background The benefits and risks of long-term testosterone administration have been a topic of much scientific and regulatory interest in recent years. Aim To assess long-term quality of life (QOL) and sexual function benefits of testosterone replacement therapy (TRT) prospectively in a diverse, multinational cohort of men with hypogonadism. Methods A multinational patient registry was used to assess long-term changes associated with TRT in middle-age and older men with hypogonadism. Comprehensive evaluations were conducted at 6, 12, 24, and 36 months after enrollment into the registry. Outcomes QOL and sexual function were evaluated by validated measures, including the Aging Males’ Symptom (AMS) Scale and the International Index of Erectile Function (IIEF). Results A total of 999 previously untreated men with hypogonadism were enrolled at 25 European centers, 750 of whom received TRT at at least one visit during the period of observation. Patients on TRT reported rapid and sustained improvements in QOL, with fewer sexual, psychological, and somatic symptoms. Modest improvements in QOL and sexual function, including erectile function, also were noted in RHYME patients not on TRT, although treated patients showed consistently greater benefit over time in all symptom domains compared with untreated patients. AMS total scores for patients on TRT were 32.8 (95% confidence interval = 31.3–34.4) compared with 36.6 (95% confidence interval = 34.8–38.5) for untreated patients (P Clinical Implications TRT-related benefits in QOL and sexual function are well maintained for up to 36 months after initiation of treatment. Strengths and Limitations The major strengths are the large, diverse patient population being treated in multidisciplinary clinical settings. The major limitation is the frequency of switching from one formulation to another. Conclusion Overall, we confirmed the broad and sustained benefits of TRT across major QOL dimensions, including sexual, somatic, and psychological health, which were sustained over 36 months in our treatment cohort. |
Databáze: | OpenAIRE |
Externí odkaz: |